Silo Pharma (SILO) holders approve lifting share cap from 6.7M

Rhea-AI Filing Summary

Silo Pharma, Inc. reported results of its August 14, 2026 annual shareholder meeting and a related charter change. Shareholders approved an amendment to the Articles of Incorporation to increase the number of authorized common shares from 6,666,667 to 250,000,000, and the company filed a Certificate of Amendment the same day to implement this change. Shareholders re-elected Eric Weisblum, Wayne Linsley, Kevin Muñoz, and Jeff Pavell to the board, ratified Salberg & Company, P.A. as independent registered public accounting firm for the year ending December 31, 2026, and approved an adjournment authorization proposal. A total of 697,308 common shares were represented in person or by proxy, constituting a quorum.

8-K Event Classification

3 items: 5.03, 5.07, 9.01

3 items

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Authorized Common Shares Before Amendment: 6,666,667 shares Authorized Common Shares After Amendment: 250,000,000 shares Shares Represented at Annual Meeting: 697,308 shares +4 more

7 metrics

Authorized Common Shares Before Amendment 6,666,667 shares Authorized common stock prior to August 14, 2026 amendment

Authorized Common Shares After Amendment 250,000,000 shares Authorized common stock following shareholder approval and filing of Certificate of Amendment

Shares Represented at Annual Meeting 697,308 shares Common shares present in person or by proxy constituting a quorum

Auditor Ratification For Votes 690,743 shares Votes for ratifying Salberg & Company, P.A. for fiscal year ending December 31, 2026

Common Stock Increase Proposal For Votes 498,224 shares Votes for amendment increasing authorized common stock to 250,000,000 shares

Common Stock Increase Proposal Against Votes 190,599 shares Votes against the authorized common stock increase proposal

Adjournment Proposal For Votes 556,797 shares Votes for authorization to adjourn the annual meeting if necessary

Key Terms

authorized shares, Certificate of Amendment, broker non-votes, quorum

4 terms

authorized shares financial

"approved an increase to the number of authorized shares of the Company’s common stock"

Authorized shares are the maximum number of shares a company is allowed to issue according to its official plan. Think of it as a company’s set limit on how many pieces of its ownership it can distribute to investors. This number helps investors understand the potential for future growth or change in the company's ownership structure.

Certificate of Amendment regulatory

"filed a Certificate of Amendment (the “Amendment”) to its Articles of Incorporation"

A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.

broker non-votes financial

"Broker Non-Votes 359,287 | | 7,489 | | 330,532"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

quorum regulatory

"A total of 697,308 shares of the Common Stock constituting a quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

FAQ

What major corporate change did Silo Pharma (SILO) shareholders approve on August 14, 2026?

Shareholders approved an amendment increasing authorized common stock from 6,666,667 to 250,000,000 shares. The company filed a Certificate of Amendment the same day to formally update its Articles of Incorporation with this higher authorized share level.

How many Silo Pharma (SILO) shares were represented at the 2026 annual meeting?

A total of 697,308 shares of Silo Pharma common stock were represented, constituting a quorum. These shares were present either in person or by valid proxies, allowing shareholders to vote on directors, auditors, and the authorized share increase.

Which directors were re-elected to Silo Pharma’s (SILO) board at the 2026 annual meeting?

Shareholders re-elected Eric Weisblum, Wayne D. Linsley, Dr. Kevin Muñoz, and Dr. Jeff Pavell. Each will serve until the next annual meeting or until a successor is duly elected and qualified, or earlier resignation, removal, or death.

Which audit firm did Silo Pharma (SILO) shareholders ratify for fiscal year 2026?

Shareholders ratified Salberg & Company, P.A. as Silo Pharma’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification vote totaled 690,743 shares for, 2,571 against, and 3,994 abstaining.

How did Silo Pharma (SILO) shareholders vote on the Common Stock Increase Proposal?

For the authorized share increase, shareholders cast 498,224 votes for, 190,599 against, and 8,485 abstentions, with no broker non-votes. This approval allowed the authorized common stock to rise to 250,000,000 shares.

What was the outcome of the adjournment authorization proposal at Silo Pharma’s (SILO) 2026 meeting?

The adjournment authorization proposal received 556,797 votes for, 131,873 against, and 8,638 abstentions, with no broker non-votes. This approval allowed potential adjournment to solicit additional proxies if needed for the other proposals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/17/2026 - 04:06 PM Accepted by SEC EDGAR 08/17/2026 - 04:05 PM Learn about SEC filing dates

false --12-31 0001514183 0001514183 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2026

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41512		27-3046338
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

677 N. Washington Boulevard Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (718) 400-9031

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On August 14, 2026, shareholders of Silo Pharma, Inc. (the “Company”) approved an increase to the number of authorized shares of the Company’s common stock, par value $0.0001 (“Common Stock”) from 6,666,667 shares to 250,000,000 shares as set forth below.

On August 14, 2026, the Company filed a Certificate of Amendment (the “Amendment”) to its Articles of Incorporation to increase its authorized shares of Common Stock from 6,666,667 shares to 250,000,000 shares.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 14, 2026, the Company held its annual meeting of shareholders, (the “Annual Meeting”) for the purpose of holding a shareholder vote on the proposals set forth below. A total of 697,308 shares of the Common Stock constituting a quorum, were represented in person or by valid proxies at the Annual Meeting.

At the Annual Meeting, the Company’s shareholders (i) re-elected each of Eric Weisblum, Wayne Linsley, Kevin Munoz and Jeff Pavell as members of the Company’s board of directors to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death; (ii) ratified the appointment of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; (iii) approved an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of our Common Stock from 6,666,667 to 250,000,000 (the “Common Stock Increase Proposal”); and (iv) approved the authorization for the adjournment of the Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals (the “Adjournment Proposal”).

The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting, as set forth in the Company’s Definitive Proxy Statement, filed with the Securities and Exchange Commission on June 30, 2026, are as follows:

Proposal 1: At the Annual Meeting, the terms of all current members of the Company’s board of directors expired. All of the four nominees for director were elected to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the four directors were as follows;

Nominee		For		Withhold		Broker Non-Votes
Eric Weisblum		359,287		7,489		330,532
Wayne D. Linsley		359,335		7,441		330,532
Dr. Kevin Muñoz		359,324		7,452		330,532
Dr. Jeff Pavell		359,383		7,393		330,532

Proposal 2: At the Annual Meeting, the shareholders approved the ratification of the appointment of Salberg & Company, P.A. (“Salberg”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The result of the votes to ratify the appointment of Salberg was as follows:

For		Against		Abstain
690,743		2,571		3,994

Proposal 3: At the Annual Meeting, the shareholders approved the Common Stock Increase Proposal.  The result of the votes to approve the Reverse Stock Split Proposal was as follows:

For		Against		Abstain		Broker Non-Votes
498,224		190,599		8,485		0

Proposal 4: At the Annual Meeting, the shareholders approved the Adjournment Proposal.  The result of the votes to approve the Adjournment Proposal was as follows:

For		Against		Abstain		Broker Non-Votes
556,797		131,873		8,638		0

1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
3.1		Certificate of Amendment.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILO PHARMA, INC.
Date: August 17, 2026	By:	/s/ Eric Weisblum
		Eric Weisblum
		Chief Executive Officer

3

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-3.1 CERTIFICATE OF AMENDMENT 8.5 KB
• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB